Peak Bio is a biopharmaceutical company that focuses on the drug development to treat Oncology and Inflammatory diseases.
Peak Bio has raised $25.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2022.
Peak Bio's investors include Palo Alto Investors, Hoyoung Huh.
Peak Bio is headquartered in Palo Alto, United States.
Peak Bio is a biopharmaceutical company that focuses on the drug development to treat Oncology and Inflammatory diseases.
Peak Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Peak Bio — Funding & Investors." VCBacked, April 28, 2022, https://www.vcbacked.co/company/peak-bio. Accessed November 13, 2026.
VCBacked. (2022). Peak Bio — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/peak-bio
{{cite web |title=Peak Bio — Funding & Investors |url=https://www.vcbacked.co/company/peak-bio |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Peak Bio? Request a listing update